U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07803705) titled 'Efficacy of Mazdutide on Fatty Pancreas' on Aug. 31.
Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel-group, single-center clinical trial designed to evaluate the efficacy and safety of mazdutide in improving fatty pancreas in patients with overweight or obesity. The study plans to enroll 194 participants with overweight or obesity, who will be randomly assigned in a 1:1 ratio to either the mazdutide plus standardized lifestyle intervention group or the placebo plus standardized lifestyle intervention group, for a treatment duration of 48 weeks. The primary efficacy endpoint is the change from baseline...